Targeting bladder disease where it matters


TARIS Biomedical® is a unique, therapeutically focused urology company developing powerful new treatments for millions of patients suffering from difficult-to-treat bladder diseases. TARIS is advancing therapies for debilitating conditions, including bladder cancer and overactive bladder, enabled by continuous local dosing where it is needed.


Year Invested: 2011
Location: Lexington, Mass.
Visit: www.tarisbiomedical.com

Recent News

January 6, 2017
TARIS Biomedical® Announces Positive Results from Ph1b Trial of TAR-200 (GemRIS™) in Patients with Muscle Invasive Bladder Cancer

August 10, 2016
TARIS Biomedical® Launches Second Phase 1b Clinical Trial of TAR-200 (GemRISTM) in Patients with Bladder Cancer

July 13, 2016
TARIS Biomedical® Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Muscle-Invasive Bladder Cancer

Read More News

Associated Team Members

Cary Pfeffer, M.D.
Partner